相似文献
1
In vitro antifungal susceptibilities of Trichosporon species.
Antimicrob Agents Chemother. 2002 Apr;46(4):1144-6. doi: 10.1128/AAC.46.4.1144-1146.2002.
2
Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
Antimicrob Agents Chemother. 2013 Oct;57(10):4841-7. doi: 10.1128/AAC.00850-13. Epub 2013 Jul 22.
3
In vitro susceptibility of Trichosporon beigelii to antifungal agents.
J Chemother. 1996 Dec;8(6):445-8. doi: 10.1179/joc.1996.8.6.445.
4
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Antimicrob Agents Chemother. 2002 Apr;46(4):1032-7. doi: 10.1128/AAC.46.4.1032-1037.2002.
5
Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates.
Diagn Microbiol Infect Dis. 2002 Jun;43(2):107-11. doi: 10.1016/s0732-8893(02)00376-0.
6
The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Virulence. 2015;6(5):476-86. doi: 10.1080/21505594.2015.1020273. Epub 2015 Mar 9.
7
In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Rev Iberoam Micol. 2005 Mar;22(1):24-8. doi: 10.1016/s1130-1406(05)70002-4.
8
In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Mycoses. 2015 Apr;58(4):209-14. doi: 10.1111/myc.12299. Epub 2015 Feb 27.
9
In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula.
J Antimicrob Chemother. 2005 Jun;55(6):1020-3. doi: 10.1093/jac/dki131. Epub 2005 Apr 21.
10
Susceptibilities to amphotericin B, fluconazole and voriconazole of Trichosporon clinical isolates.
Mycopathologia. 2012 Aug;174(2):121-30. doi: 10.1007/s11046-012-9525-z. Epub 2012 Feb 9.
引用本文的文献
1
Broad-Spectrum Activity and Mechanisms of Action of SQ109 on a Variety of Fungi.
ACS Infect Dis. 2025 Jun 13;11(6):1662-1672. doi: 10.1021/acsinfecdis.5c00210. Epub 2025 May 14.
2
Broad-Spectrum Activity and Mechanisms of Action of SQ109 on a Variety of Fungi.
bioRxiv. 2025 Feb 3:2025.02.03.636131. doi: 10.1101/2025.02.03.636131.
3
The Prevalence and Risk Factors of Trichosporonosis at King Abdulaziz University Hospital.
Int J Gen Med. 2024 Apr 3;17:1297-1310. doi: 10.2147/IJGM.S449511. eCollection 2024.
4
A Rare Case of a Retroperitoneal Abscess Due to Trichosporon spp. in an Immunocompetent Patient.
Cureus. 2024 Mar 6;16(3):e55656. doi: 10.7759/cureus.55656. eCollection 2024 Mar.
5
Metabolome and Transcriptome Combinatory Profiling Reveals Fluconazole Resistance Mechanisms of and the Role of Farnesol in Fluconazole Tolerance.
Microorganisms. 2023 Nov 17;11(11):2798. doi: 10.3390/microorganisms11112798.
6
Trichosporon asahii causing subcutaneous mycoses in an immunocompetent patient: case report and a minireview.
Braz J Microbiol. 2022 Sep;53(3):1221-1229. doi: 10.1007/s42770-022-00737-x. Epub 2022 Apr 5.
7
Epidemiological study of infections over the past 23 years.
Epidemiol Infect. 2020 Jul 24;148:e169. doi: 10.1017/S0950268820001624.
8
Complicated urinary tract infection by .
Med Mycol Case Rep. 2019 Apr 28;24:86-89. doi: 10.1016/j.mmcr.2019.04.014. eCollection 2019 Jun.
9
Comparison of 21-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA Sequencing for a Wide Range of Clinically Isolated Yeast Species: Improved Identification by Combining 21-Plex PCR and API 20C AUX as an Alternative Strategy for Developing Countries.
Front Cell Infect Microbiol. 2019 Feb 15;9:21. doi: 10.3389/fcimb.2019.00021. eCollection 2019.
10
Posaconazole: An Update of Its Clinical Use.
Pharmacy (Basel). 2015 Oct 21;3(4):210-268. doi: 10.3390/pharmacy3040210.
本文引用的文献
1
Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia.
Clin Infect Dis. 2001 Sep 1;33(5):E28-30. doi: 10.1086/322640. Epub 2001 Jul 26.
2
Transmission of Trichosporon asahii oesophagitis by a contaminated endoscope.
Mycoses. 2001;44(1-2):13-21. doi: 10.1046/j.1439-0507.2001.00614.x.
3
Trichosporon species infection in bone marrow transplanted patients.
Diagn Microbiol Infect Dis. 2001 Mar;39(3):161-4. doi: 10.1016/s0732-8893(01)00215-2.
4
A case of Trichosporon beigelii endocarditis.
Eur J Clin Microbiol Infect Dis. 2001 Feb;20(2):139-42. doi: 10.1007/pl00011245.
5
In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
J Antibiot (Tokyo). 2000 Oct;53(10):1175-81. doi: 10.7164/antibiotics.53.1175.
6
Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Diagn Microbiol Infect Dis. 2000 Oct;38(2):101-7. doi: 10.1016/s0732-8893(00)00177-2.
7
Trichosporon beigelii infection: experience in a regional burn center.
Burns. 2000 Aug;26(5):483-6. doi: 10.1016/s0305-4179(99)00181-3.
8
In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test.
Mycoses. 1999;42(11-12):629-39. doi: 10.1046/j.1439-0507.1999.00510.x.
9
Invasive yeast infections other than Candida spp. in acute leukaemia.
J Hosp Infect. 1999 Mar;41(3):181-94. doi: 10.1016/s0195-6701(99)90015-4.
10
In vitro activity of voriconazole against selected fungi.
Med Mycol. 1998 Aug;36(4):239-42.
Zotero 插件